Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    September 2017
  1. TAGAWA N, Sugiyama E, Tajima M, Sasaki Y, et al
    Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.
    Cancer Chemother Pharmacol. 2017 Sep 1. doi: 10.1007/s00280-017-3425.
    >> Share

    August 2017
  2. HUANG S, Wang D, Zhang S, Huang X, et al
    Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Cancer Chemother Pharmacol. 2017 Aug 4. doi: 10.1007/s00280-017-3393.
    >> Share

  3. PARK WS, Park GJ, Han S, Ban S, et al
    Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
    Cancer Chemother Pharmacol. 2017;80:363-369.
    >> Share

    July 2017
  4. PANIS C, Binato R, Correa S, Victorino VJ, et al
    Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer.
    Cancer Chemother Pharmacol. 2017 Jul 8. doi: 10.1007/s00280-017-3384.
    >> Share

  5. PEER CJ, Lee JM, Roth J, Rodgers L, et al
    Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
    Cancer Chemother Pharmacol. 2017;80:165-175.
    >> Share

  6. SMIYUN G, Azarenko O, Miller H, Rifkind A, et al
    betaIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Cancer Chemother Pharmacol. 2017;80:151-164.
    >> Share

    June 2017
  7. TSYGANOV MM, Freidin MB, Ibragimova MK, Deryusheva IV, et al
    Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer.
    Cancer Chemother Pharmacol. 2017 Jun 10. doi: 10.1007/s00280-017-3354.
    >> Share

  8. TANABE Y, Shimizu C, Hamada A, Hashimoto K, et al
    Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
    Cancer Chemother Pharmacol. 2017;79:1179-1186.
    >> Share

    May 2017
  9. XU YL, Yao R, Li J, Zhou YD, et al
    FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2017 May 10. doi: 10.1007/s00280-017-3319.
    >> Share

    April 2017
  10. MOUSAVI E, Tavakolfar S, Almasirad A, Kooshafar Z, et al
    In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells.
    Cancer Chemother Pharmacol. 2017 Apr 27. doi: 10.1007/s00280-017-3318.
    >> Share

  11. REN YQ, Wang HJ, Zhang YQ, Liu YB, et al
    WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
    Cancer Chemother Pharmacol. 2017 Apr 8. doi: 10.1007/s00280-017-3302.
    >> Share

    March 2017
  12. CHE J, Huang Y, Xu C, Zhang P, et al
    Increased ceramide production sensitizes breast cancer cell response to chemotherapy.
    Cancer Chemother Pharmacol. 2017 Mar 29. doi: 10.1007/s00280-017-3292.
    >> Share

  13. ROCCA A, Cecconetto L, Passardi A, Melegari E, et al
    Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3279.
    >> Share

  14. TANDIA M, Mhiri A, Paule B, Saffroy R, et al
    Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3268.
    >> Share

    February 2017
  15. WANG Z, Chen J, Zhong MZ, Huang J, et al
    Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
    Cancer Chemother Pharmacol. 2017 Feb 27. doi: 10.1007/s00280-017-3248.
    >> Share

  16. KONG X
    Reply to: comment on "Meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer".
    Cancer Chemother Pharmacol. 2017 Feb 22. doi: 10.1007/s00280-016-3230.
    >> Share

    January 2017
  17. QUARTINO AL, Li H, Jin JY, Wada DR, et al
    Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
    Cancer Chemother Pharmacol. 2017 Jan 10. doi: 10.1007/s00280-016-3218.
    >> Share

  18. ZHANG HY, Liang F, Zhang JW, Wang F, et al
    Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3208.
    >> Share

  19. CARGNIN S, Terrazzino S
    Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3229.
    >> Share

  20. TAKAHASHI S, Kobayashi T, Tomomatsu J, Ito Y, et al
    LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.
    Cancer Chemother Pharmacol. 2017;79:131-138.
    >> Share

  21. CHAN JC, Ong PS, Lim P, Teng PX, et al
    Synergistic disruption of ERalpha/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
    Cancer Chemother Pharmacol. 2017;79:117-130.
    >> Share

    October 2016
  22. KONG X, Li Z, Li X
    GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2016.
    >> Share

    August 2016
  23. SONG JG, Lee YS, Park JA, Lee EH, et al
    Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Cancer Chemother Pharmacol. 2016.
    >> Share

  24. PARK JH, Kang MJ, Ahn JH, Kim JE, et al
    Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afte
    Cancer Chemother Pharmacol. 2016.
    >> Share

    July 2016
  25. ZHANG X, Bai W
    Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Cancer Chemother Pharmacol. 2016.
    >> Share

  26. LI C, Wang B, Lu D, Jin JY, et al
    Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    >> Share

    June 2016
  27. YOSHITOMI S, Taira N, Doihara H, Mizoo T, et al
    A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016